الإحصائيات الأساسية
| CIK | 1711933 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Akoya Biosciences, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in |
|
| July 8, 2025 |
As filed with the Securities and Exchange Commission on July 8, 2025 As filed with the Securities and Exchange Commission on July 8, 2025 Registration No. |
|
| July 8, 2025 |
As filed with the Securities and Exchange Commission on July 8, 2025 As filed with the Securities and Exchange Commission on July 8, 2025 Registration No. |
|
| July 8, 2025 |
As filed with the Securities and Exchange Commission on July 8, 2025 As filed with the Securities and Exchange Commission on July 8, 2025 Registration No. |
|
| July 8, 2025 |
CERTIFICATE OF INCORPORATION WELLFLEET MERGER SUB, INC. Exhibit 3.1 Execution Version CERTIFICATE OF INCORPORATION OF WELLFLEET MERGER SUB, INC. The undersigned does hereby make and acknowledge this Certificate of Incorporation for the purpose of forming a business corporation pursuant to Section 102 of the General Corporation Law of the State of Delaware (the “DGCL”). ARTICLE I NAME The name of the Corporation is Wellfleet Merger Sub, Inc. ARTICLE II |
|
| July 8, 2025 |
Exhibit 3.2 Final Version BYLAWS OF WELLFLEET MERGER SUB, INC. a Delaware Corporation (hereinafter referred to as the “Corporation”) ARTICLE I OFFICES Section 1. Registered Office. The registered office and the registered agent of the Corporation are as set forth in the Certificate of Incorporation. Section 2. Other Offices. The Corporation may also have offices at such other pla |
|
| July 8, 2025 |
As filed with the Securities and Exchange Commission on July 8, 2025 As filed with the Securities and Exchange Commission on July 8, 2025 Registration No. |
|
| July 8, 2025 |
As filed with the Securities and Exchange Commission on July 8, 2025 As filed with the Securities and Exchange Commission on July 8, 2025 Registration No. |
|
| July 8, 2025 |
As filed with the Securities and Exchange Commission on July 8, 2025 As filed with the Securities and Exchange Commission on July 8, 2025 Registration No. |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 8, 2025 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2025 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 16, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2025 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2025 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2025 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 12, 2025 |
Quanterix Releases Financial Results for the First Quarter of 2025 Exhibit 99.1 Quanterix Releases Financial Results for the First Quarter of 2025 BILLERICA, Mass. – May 12, 2025 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, |
|
| May 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2025 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 12, 2025 |
Exhibit 99.1 Akoya Biosciences Reports First Quarter 2025 Financial Results May 12, 2025 MARLBOROUGH, Mass.— Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. “Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our |
|
| May 12, 2025 |
Filed by Akoya Biosciences, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Akoya Biosciences, Inc. Subject Company: Akoya Biosciences, Inc. SEC File No.: 001-40344 Date: May 12, 2025 Akoya Biosciences Reports First Quarter 2025 Financial Results May 12, 2025 MARLBOROUGH, Mass.— Akoya Biosciences, |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| April 29, 2025 |
EXHIBIT 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among QUANTERIX CORPORATION WELLFLEET MERGER SUB, INC. and AKOYA BIOSCIENCES, INC. Dated as of April 28, 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.01 Definitions 2 1.02 Other Definitional Provisions 16 ARTICLE 2 THE MERGER 17 2.01 Shares of Merger Sub 17 2.02 The Merger 17 2.03 Closing 17 2.04 Effective Time 18 2.05 Effect |
|
| April 29, 2025 |
EXHIBIT 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among QUANTERIX CORPORATION WELLFLEET MERGER SUB, INC. and AKOYA BIOSCIENCES, INC. Dated as of April 28, 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.01 Definitions 2 1.02 Other Definitional Provisions 16 ARTICLE 2 THE MERGER 17 2.01 Shares of Merger Sub 17 2.02 The Merger 17 2.03 Closing 17 2.04 Effective Time 18 2.05 Effect |
|
| April 29, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Quanterix and Akoya Biosciences Announce Amended Merger Agreement Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination BILLERICA, Mass. and MARLBOROUGH, Mass. – April 29, 2025 – Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (N |
|
| April 29, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Quanterix and Akoya Biosciences Announce Amended Merger Agreement Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination BILLERICA, Mass. and MARLBOROUGH, Mass. – April 29, 2025 – Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (N |
|
| April 29, 2025 |
EXHIBIT 10.2 AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT, dated as of April 28, 2025 (this “Amendment”), is made by and between (i) Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and (ii) Quanterix Corporation, a Delaware corporation (“Purchaser”). The Company and Purchaser are referred to herein individually as a “Party, |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 28, 2025 Date of Report (Date of earliest event reported) QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 29, 2025 |
EXHIBIT 10.2 AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT, dated as of April 28, 2025 (this “Amendment”), is made by and between (i) Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and (ii) Quanterix Corporation, a Delaware corporation (“Purchaser”). The Company and Purchaser are referred to herein individually as a “Party, |
|
| April 29, 2025 |
EXHIBIT 10.1 CONSENT AND WAIVER This CONSENT AND WAIVER (this “Consent and Waiver”) is made and entered into as of April 28, 2025, by each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”) and Quanterix Corporation, a Delaware corporation (“Parent”). WHEREAS, Parent, Wellfleet Merger Sub, Inc., a Delaware corporation |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2025 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| April 29, 2025 |
Exhibit 99.2 Amended Merger Agreement Synergistic Combination Delivering Compelling Strategic and Financial Benefits and Long - Term Value for Stockholders April 2025 Legal Information 2 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed acquisition of Akoya Biosciences, Inc. (“Akoya” or “AKYA”) by Quanterix Corporation (“Quanterix” or “QTRX”), Quanterix will file with the Securities |
|
| April 29, 2025 |
EXHIBIT 10.2 AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT, dated as of April 28, 2025 (this “Amendment”), is made by and between (i) Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and (ii) Quanterix Corporation, a Delaware corporation (“Purchaser”). The Company and Purchaser are referred to herein individually as a “Party, |
|
| April 29, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Quanterix and Akoya Biosciences Announce Amended Merger Agreement Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination BILLERICA, Mass. and MARLBOROUGH, Mass. – April 29, 2025 – Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (N |
|
| April 29, 2025 |
Exhibit 10.3 Execution Version VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of April 28, 2025 by and among Quanterix Corporation, a Delaware corporation (“Parent”), and each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”). WHEREAS, each Stockholder is, |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2025 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| April 29, 2025 |
EXHIBIT 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among QUANTERIX CORPORATION WELLFLEET MERGER SUB, INC. and AKOYA BIOSCIENCES, INC. Dated as of April 28, 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.01 Definitions 2 1.02 Other Definitional Provisions 16 ARTICLE 2 THE MERGER 17 2.01 Shares of Merger Sub 17 2.02 The Merger 17 2.03 Closing 17 2.04 Effective Time 18 2.05 Effect |
|
| April 28, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| April 15, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 4, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT BY AND BETWEEN QUANTERIX CORPORATION AND aKOYA BIOSCIENCES, INC. Dated as of April 2, 2025 TABLE OF CONTENTS Article I DEFINITIONS 2 Section 1.1 Definitions 2 Section 1.2 Construction 10 Article II PURCHASE AND SALE 11 Section 2.1 The Purchase and Sale 11 Section 2.2 Closing 12 Article III REPRESENTATIONS AND WARRANTIES OF THE COMPANY 13 Section 3.1 Organ |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 2, 2025 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission F |
|
| April 4, 2025 |
Form of Registration Rights Agreement Exhibit 10.3 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of [●], by and between Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and Quanterix Corporation (the “Holder”). The Company and the Holder are referred to each as a “Party” and collectively herein as the “Parties.” Capitalized terms used herein and |
|
| April 4, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT BY AND BETWEEN QUANTERIX CORPORATION AND AKOYA BIOSCIENCES, INC. Dated as of April 2, 2025 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Construction 10 ARTICLE II PURCHASE AND SALE 11 Section 2.1 The Purchase and Sale 11 Section 2.2 Closing 12 ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY 13 Section 3.1 Organ |
|
| April 4, 2025 |
Form of Subordination Agreement Exhibit 10.4 Execution Version SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT (this “Agreement”) is entered into as of this [●] day of [●], 202[●], by and among QUANTERIX CORPORATION, a Delaware corporation (“Subordinated Lender”), AKOYA BIOSCIENCES, INC., a Delaware corporation (“Borrower”), and MIDCAP FINANCIAL TRUST, a Delaware statutory trust, as Agent for the financial institutions or o |
|
| April 4, 2025 |
Exhibit 10.2 THE INDEBTEDNESS EVIDENCED BY THIS NOTE IS SUBJECT TO THE TERMS OF A SUBORDINATION AGREEMENT BETWEEN THE HOLDER (AS DEFINED BELOW) AND MIDCAP FINANCIAL TRUST. THIS NOTE, AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE APPLICABLE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE PLEDGED, SOLD |
|
| April 4, 2025 |
Form of Subordination Agreement Exhibit 10.4 FORM OF SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT (this “Agreement”) is entered into as of this [●] day of [●], 202[●], by and among QUANTERIX CORPORATION, a Delaware corporation (“Subordinated Lender”), AKOYA BIOSCIENCES, INC., a Delaware corporation (“Borrower”), and MIDCAP FINANCIAL TRUST, a Delaware statutory trust, as Agent for the financial institutions or other entit |
|
| April 4, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT BY AND BETWEEN QUANTERIX CORPORATION AND aKOYA BIOSCIENCES, INC. Dated as of April 2, 2025 TABLE OF CONTENTS Article I DEFINITIONS 2 Section 1.1 Definitions 2 Section 1.2 Construction 10 Article II PURCHASE AND SALE 11 Section 2.1 The Purchase and Sale 11 Section 2.2 Closing 12 Article III REPRESENTATIONS AND WARRANTIES OF THE COMPANY 13 Section 3.1 Organ |
|
| April 4, 2025 |
Form of Registration Rights Agreement Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of [●], by and between Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and Quanterix Corporation (the “Holder”). The Company and the Holder are referred to each as a “Party” and collectively herein as the “Parties.” Capitalized terms used herein and not othe |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 2, 2025 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission F |
|
| April 4, 2025 |
Exhibit 10.2 THE INDEBTEDNESS EVIDENCED BY THIS NOTE IS SUBJECT TO THE TERMS OF A SUBORDINATION AGREEMENT BETWEEN THE HOLDER (AS DEFINED BELOW) AND MIDCAP FINANCIAL TRUST. THIS NOTE, AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE APPLICABLE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE PLEDGED, SOLD |
|
| April 4, 2025 |
Form of Subordination Agreement Exhibit 10.4 Execution Version SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT (this “Agreement”) is entered into as of this [●] day of [●], 202[●], by and among QUANTERIX CORPORATION, a Delaware corporation (“Subordinated Lender”), AKOYA BIOSCIENCES, INC., a Delaware corporation (“Borrower”), and MIDCAP FINANCIAL TRUST, a Delaware statutory trust, as Agent for the financial institutions or o |
|
| April 4, 2025 |
Form of Registration Rights Agreement Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of [●], by and between Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and Quanterix Corporation (the “Holder”). The Company and the Holder are referred to each as a “Party” and collectively herein as the “Parties.” Capitalized terms used herein and not othe |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 4, 2025 |
Exhibit 10.2 THE INDEBTEDNESS EVIDENCED BY THIS NOTE IS SUBJECT TO THE TERMS OF A SUBORDINATION AGREEMENT BETWEEN THE HOLDER (AS DEFINED BELOW) AND MIDCAP FINANCIAL TRUST. THIS NOTE, AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE APPLICABLE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE PLEDGED, SOLD |
|
| March 18, 2025 |
Filed by Quanterix Corporation pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Akoya Biosciences, Inc. |
|
| March 17, 2025 |
Exhibit 10.24 Certain information, as identified by [***], has been excluded from this agreement because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT NO. 5 to CREDIT AND SECURITY AGREEMENT (TERM LOAN) This AMENDMENT No. 5 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of the 1st day of November, 2024, by and among AKOYA |
|
| March 17, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Akoya Biosciences, Inc. |
|
| March 17, 2025 |
Offer Letter, dated September 16, 2021, by and between the Registrant and Pascal Bamford Exhibit 10.21 September 1, 2021 Pascal Bamford [***] [***] [***] Dear Pascal, We are very excited about the prospects of your joining Akoya Biosciences, Inc. Should you accept this offer and upon successful completion of a pre-employment background check and drug screen we look forward to having you join the company on September 13, 2021. This letter confirms the terms of your employment. Position |
|
| March 17, 2025 |
Exhibit 99.1 Quanterix Releases Financial Results for the Fourth Quarter of 2024 Delivers seventh consecutive quarter of double-digit revenue growth BILLERICA, Mass. – March 17, 2025 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter ended December 31, 2024. “During the |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2025 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| March 17, 2025 |
Exhibit 99.4 AKOYA BIOSCIENCES, INC. NOTICE OF GRANT OF RESTRICTED STOCK UNITS (For U.S. Participants) Akoya Biosciences, Inc. (the “Company”) has granted to the Participant an award (the “Award”) of certain units pursuant to the Akoya Biosciences, Inc. 2021 Equity Incentive Plan (the “Plan”), each of which represents the right to receive on the applicable Settlement Date one (1) share of Stock, a |
|
| March 17, 2025 |
Director Compensation Policy, adopted October 2, 2024 Exhibit 10.22 AKOYA BIOSCIENCES, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Adopted October 2, 2024 Position Annual Retainer Board Membership $ 40,000 Non-Executive Chair of the Board $ 40,000 Chair of Audit Committee $ 20,000 Chair of the Compensation Committee $ 15,000 Chair of the Innovation and Technology Committee $ 15,000 Chair of the Corporate Governance and Nominating Committee $ 10,00 |
|
| March 17, 2025 |
Form of Stock Option Grant Notice and Stock Option Agreement for 2021 Equity Incentive Plan Exhibit 99.3 Akoya Biosciences, Inc. NOTICE OF GRANT OF STOCK OPTION Akoya Biosciences, Inc. (the “Company”) has granted to the Participant an option (the “Option”) to purchase certain shares of Stock pursuant to the Akoya Biosciences, Inc. 2021 Equity Incentive Plan (the “Plan”), as follows: Participant: Employee ID: Date of Grant Number of Option Shares* Exercise Price: Vest Start Date: Option E |
|
| March 17, 2025 |
Exhibit 99.1 Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results March 17, 2025 MARLBOROUGH, Mass.— Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40 |
|
| March 17, 2025 |
Insider Trading Policy, adopted May 18, 2023 Exhibit 19.1 INSIDER TRADING POLICY As adopted by the Board of Directors as of May 18, 2023 Table of Contents Page Section 1. All Employees, Officers, Directors and their Family Members and Affiliates Are Subject to this Policy 1 Section 2. Trading in Akoya Securities While in Possession of Material Nonpublic Information is Prohibited 1 Section 3. Trading in Akoya Securities 1 Section 4. Trading i |
|
| March 17, 2025 |
As filed with the Securities and Exchange Commission on March 17, 2025 As filed with the Securities and Exchange Commission on March 17, 2025 Registration No. |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 3, 2025 |
EXHIBIT 99.1 Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition Comments on Director Nominations Received from Kent Lake BILLERICA, Mass. March 3, 2025 - Quanterix Corporation (NASDAQ: QTRX) (“Quanterix” or the “Company”), a company fueling scientific discovery through ultra-sensitive biomarker detection, today reiterated the strategic and financial benefits of its proposed |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2025 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commissi |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2025 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commissi |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| February 11, 2025 |
feb112025425filingfinal Filed by Quanterix Corporation pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Akoya Biosciences, Inc. |
|
| January 16, 2025 |
SCHEDULE A Directors and Executive Officers of Akoya Biosciences, Inc. Exhibit 99.1 SCHEDULE A Directors and Executive Officers of Akoya Biosciences, Inc. Name Position Brian McKelligon President, Chief Executive Officer and Director Johnny Elk Chief Financial Officer Jennifer Kamocsay General Counsel Pascal Bamford Chief Clinical Officer Niro Ramachandran Chief Business Officer Robert G. Shepler Director, Chairman of the Board Thomas Raffin Director Thomas P. Schnet |
|
| January 16, 2025 |
Talking Points and Customer-Facing FAQs Filed by Akoya Biosciences, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Akoya Biosciences, Inc. Subject Company: Akoya Biosciences, Inc. SEC File No.: 001-40344 Date: January 15, 2025 Talking Points and Customer-Facing FAQs Talking Points for Customer Conversations. Use the appropriate talking |
|
| January 16, 2025 |
jpmakoyarule425filing Filed by Quanterix Corporation pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Akoya Biosciences, Inc. |
|
| January 16, 2025 |
BOARD OF DIRECTORS AND EXECUTIVE OFFICERS OF QUANTERIX SCHEDULE A BOARD OF DIRECTORS AND EXECUTIVE OFFICERS OF QUANTERIX The name, present principal occupation or employment and citizenship of each member of the Board of Directors and each executive officer of Quanterix are as set forth below. |
|
| January 15, 2025 |
Filed by Akoya Biosciences, Inc. Filed by Akoya Biosciences, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Akoya Biosciences, Inc. Subject Company: Akoya Biosciences, Inc. SEC File No.: 001-40344 Date: January 15, 2025 Subject: Akoya Biosciences to Merge with Quanterix Dear Valued Akoya Customer, I’m excited to share that Akoya |
|
| January 14, 2025 |
EXHIBIT 99.1 Quanterix Provides Update on Financial Performance Company announced preliminary Q4 2024 revenue of approximately $34.9 million and FY 2024 revenue of approximately $137.2 million, representing 12% year-over-year growth for the full year BILLERICA, Mass. – Jan. 14, 2025 – Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker dete |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| January 10, 2025 |
Exhibit 10.1 Execution version VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of January 9, 2025, by and among Akoya Biosciences, Inc., a Delaware corporation (the “Company”) and each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”). WHEREAS, each Stockho |
|
| January 10, 2025 |
Form of Quanterix Voting Agreement. Exhibit 10.1 Execution version VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of January 9, 2025, by and among Akoya Biosciences, Inc., a Delaware corporation (the “Company”) and each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”). WHEREAS, each Stockho |
|
| January 10, 2025 |
Why is Quanterix acquiring Akoya? EXHIBIT 99.5 1.Why is Quanterix acquiring Akoya? •The acquisition of Akoya is consistent with our GET strategy and part of the natural evolution of our company. •This is a pivotal step forward in the holistic understanding and treatment of disease. By integrating Akoya’s spatial biology capabilities in tissue with our advanced tools for blood detection, we will create the first integrated solution |
|
| January 10, 2025 |
Exhibit 99.1 NOT FOR IMMEDIATE RELEASE Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling op |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2025 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| January 10, 2025 |
Exhibit 99.1 NOT FOR IMMEDIATE RELEASE Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling op |
|
| January 10, 2025 |
Exhibit 2.1 Execution version AGREEMENT AND PLAN OF MERGER by and among QUANTERIX CORPORATION WELLFLEET MERGER SUB, INC. and AKOYA BIOSCIENCES, INC. Dated as of January 9, 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.01 Definitions 2 1.02 Other Definitional Provisions 15 ARTICLE 2 THE MERGER 16 2.01 Shares of Merger Sub 16 2.02 The Merger 16 2.03 Closing 17 2.04 Effective Time 17 2.05 Effects |
|
| January 10, 2025 |
Subject: Important Update: Quanterix to Acquire Akoya EXHIBIT 99.4 Subject: Important Update: Quanterix to Acquire Akoya [INSERT NAME], I am writing to share an exciting update from Quanterix – we have announced our plans to acquire Akoya Biosciences, Inc., a company that shares our mission to revolutionize the way we understand and treat disease. Below please find the press release we issued with additional details. This is a logical next step for Q |
|
| January 10, 2025 |
Financial Statements and Exhibits, Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2025 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| January 10, 2025 |
EXHIBIT 10.2 Execution version STOCKHOLDER LOCK-UP AGREEMENT January 9, 2025 Quanterix Corporation 900 Middlesex Turnpike Billerica, MA Attention: Legal Department Email: [email protected] To the addressee set forth above: The undersigned understands that, on the date hereof, Quanterix Corporation, a Delaware corporation (“Parent”), Wellfleet Merger Sub, Inc., a Delaware corporation and a wholly |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| January 10, 2025 |
EXHIBIT 10.1 VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of January 9, 2025 by and among Quanterix Corporation, a Delaware corporation (“Parent”) and each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”). WHEREAS, each Stockholder is, as of the date he |
|
| January 10, 2025 |
EXHIBIT 99.1 Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across transla |
|
| January 10, 2025 |
Filed by Akoya Biosciences, Inc. Filed by Akoya Biosciences, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Akoya Biosciences, Inc. Subject Company: Akoya Biosciences, Inc. SEC File No.: 001-40344 Date: January 10, 2025 Dear Akoyans, I hope this note finds all of you well and Happy New Year to each of you. We are kicking off 2025 |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission F |
|
| January 10, 2025 |
EXHIBIT 99.1 Operator^ Hello, and welcome to today's call to discuss Quanterix's acquisition of Akoya Biosciences. At this time, our participants have been placed in listen-only mode. The call will be open for your questions following the prepared remarks. As a reminder, this conference call is being recorded and the press release and slide presentation regarding the transactions are available at |
|
| January 10, 2025 |
First Integrated Solution for Ultra- Sensitive Detection of Blood and Tissue Based Protein Biomarkers Uniquely positioned to speed up market development of new diagnostic testing solutions January 10, 2025 2 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed transaction, Quanterix Corporation (“Quanterix” or “QTRX”) will file with the U. |
|
| January 10, 2025 |
EXHIBIT 99.2 Team, Diseases like cancer begin in tissue, spread to blood and often end up in other organs such as lung and liver that ultimately take life. To effectively detect and treat disease, we must measure signals as they follow this pathway. Our vision is to bring clinical and anatomical pathology together to solve this problem. Today we announced our plans to acquire Akoya Biosciences. By |
|
| January 10, 2025 |
EXHIBIT 2.1 Execution version AGREEMENT AND PLAN OF MERGER by and among QUANTERIX CORPORATION WELLFLEET MERGER SUB, INC. and AKOYA BIOSCIENCES, INC. Dated as of January 9, 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.01 Definitions 2 1.02 Other Definitional Provisions 15 ARTICLE 2 THE MERGER 16 2.01 Shares of Merger Sub 16 2.02 The Merger 16 2.03 Closing 17 2.04 Effective Time 17 2.05 Effects |
|
| January 10, 2025 |
Subject: Important Update: Quanterix to Acquire Akoya EXHIBIT 99.3 Subject: Important Update: Quanterix to Acquire Akoya [INSERT NAME], I am writing to share an exciting update from Quanterix – we have announced plans to acquire Akoya Biosciences, Inc., a company that shares our mission to revolutionize the way we understand and treat disease. Below please find the press release we issued with additional details. Together, we’re creating the first pl |
|
| January 10, 2025 |
IMPORTANT ADDITIONAL INFORMATION Exhibit 99.6 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed transaction, Quanterix will file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “registration statement”), which will contain a joint proxy statement of Quanterix and Akoya and a prospectus of Quanterix (the “joint proxy statement/prospectus”), and each of Quanterix |
|
| January 10, 2025 |
Exhibit 2.1 Execution version AGREEMENT AND PLAN OF MERGER by and among QUANTERIX CORPORATION WELLFLEET MERGER SUB, INC. and AKOYA BIOSCIENCES, INC. Dated as of January 9, 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.01 Definitions 2 1.02 Other Definitional Provisions 15 ARTICLE 2 THE MERGER 16 2.01 Shares of Merger Sub 16 2.02 The Merger 16 2.03 Closing 17 2.04 Effective Time 17 2.05 Effects |
|
| December 13, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 11, 2024 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commissi |
|
| December 13, 2024 |
Form Indemnification Agreement Exhibit 10.1 AKOYA BIOSCIENCES, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement, dated , 2024, is made between Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and [] (the “Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of talented and experienced individuals, such as Indemnitee, to serve as directors and officers of the Company |
|
| November 14, 2024 |
Exhibit 10.1 Certain information, as identified by [***], has been excluded from this agreement because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT NO. 4 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) This AMENDMENT NO. 4 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of the 31st day of July, 2024, by and among AKOYA BIO |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2024 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commissi |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 14, 2024 |
Exhibit 99.1 Akoya Biosciences Reports Third Quarter 2024 Financial Results November 14, 2024 MARLBOROUGH, Mass.— Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024. “Our third-quarter results came in below expectations, largely due to ongoing capital equipment purchase constraints se |
|
| November 4, 2024 |
AKYA / Akoya Biosciences, Inc. / Schindel Yair Chaim - SC 13G/A Passive Investment SC 13G/A 1 zk2432211.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Akoya Biosciences, Inc. (Name of Issuer) Common Stock, Par Value $0.00001 per Share (Title of Class of Securities) 00974H104 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 2, 2024 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| August 28, 2024 |
AKYA / Akoya Biosciences, Inc. / Blue Water Life Science Advisors, LLC Passive Investment SC 13G 1 bwls-akya123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Akoya Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 00974H104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 6, 2024 |
Exhibit 10.1 AKOYA BIOSCIENCES, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Adopted May 16, 2024 Position Annual Retainer Board Membership $ 40,000 Non-Executive Chair of the Board $ 40,000 Chair of Audit Committee $ 20,000 Chair of the Compensation Committee $ 15,000 Chair of the Innovation and Technology Committee $ 15,000 Chair of the Corporate Governance and Nominating Committee $ 10,000 Au |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2024 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission F |
|
| August 5, 2024 |
Exhibit 99.1 Akoya Biosciences Reports Second Quarter 2024 Financial Results August 5, 2024 MARLBOROUGH, Mass.— Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30, 2024. “Our second-quarter revenue showed a strong rebound with 26% sequential top-line growth and a stable year-over-year performan |
|
| June 4, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 4, 2024 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 13, 2024 |
Bottom of Form Bottom of Form Bottom of Form Exhibit 99.1 Akoya Biosciences Reports First Quarter 2024 Financial Results May 13, 2024 MARLBOROUGH, Mass.— Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2024. Business Highlights ● Revenue was $18.4 million in the first quarter of 2024, compared to $21.4 million in the prior year period |
|
| May 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2024 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 23, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| March 5, 2024 |
As filed with the Securities and Exchange Commission on March 4, 2024 As filed with the Securities and Exchange Commission on March 4, 2024 Registration No. |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40 |
|
| March 5, 2024 |
Clawback Policy, adopted August 31, 2023 Exhibit 97.1 AKOYA BIOSCIENCES, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE COMPENSATION (Adopted August 31, 2023) 1.INTRODUCTION Akoya Biosciences, Inc. (the “Company”) is adopting this policy (this “Policy”) to provide for the Company’s recovery of certain Incentive Compensation (as defined below) erroneously awarded to Affected Officers (as defined below) under certain circumstanc |
|
| March 5, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Akoya Biosciences, Inc. |
|
| March 4, 2024 |
Exhibit 99.1 Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook March 4, 2024 Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 million Guiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024 MARLBOROUGH, Mass.— Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today an |
|
| March 4, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 4, 2024 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission F |
|
| February 14, 2024 |
AKYA / Akoya Biosciences, Inc. / Telegraph Hill Partners III, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246170d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Akoya Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 00974H104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 12, 2024 |
AKYA / Akoya Biosciences, Inc. / PSC Capital Partners LLC - 13G AMENDMENT Passive Investment SC 13G/A 1 akoya.htm 13G AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 (Amendment #2) Akoya Biosciences, Inc. - (Name of Issuer) Common Stock, par value $0.00001 per share - (Title of Class of Securities) 00974H104 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2024 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| January 10, 2024 |
Exhibit 99.1 Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board Leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational, clinical, and diagnostic applications of Akoya’s spatial biology solutions MARLBOROUGH, Mass. (GLOBE NEWSWIRE) January 10, |
|
| January 8, 2024 |
Exhibit 99.1 Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook MARLBOROUGH, Mass., (GLOBE NEWSWIRE) January 7, 2024 - Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2023, and projected year |
|
| January 8, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 7, 2024 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| January 3, 2024 |
AKYA / Akoya Biosciences, Inc. / Schindel Yair Chaim - SC 13G/A Passive Investment SC 13G/A 1 zk2430729.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Akoya Biosciences, Inc. (Name of Issuer) Common Stock, Par Value $0.00001 per Share (Title of Class of Securities) 00974H104 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate b |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2023 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commissio |
|
| November 8, 2023 |
Exhibit 99.1 Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance November 8, 2023 Q3 2023 revenue $25.2 million, 34% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million MARLBOROUGH, Mass.— Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarte |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 31, 2023 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| September 6, 2023 |
Exhibit 3.1 AMENDED AND RESTATED Bylaws of AKOYA BIOSCIENCES, INC. Effective as of August 31, 2023 ARTICLE I CORPORATE OFFICES 1.1 Registered Office. The address of the registered office of Akoya Biosciences, Inc. (the “Corporation”) in the State of Delaware, and the name of its registered agent at such address, shall be as set forth in the Corporation’s certificate of incorporation, as the sa |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2023 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| August 7, 2023 |
Exhibit 99.1 Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance August 7, 2023 Q2 2023 revenue $23.5 million, 31% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million MARLBOROUGH, Mass.— Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarte |
|
| July 5, 2023 |
Separation Agreement and Release, dated July 3, 2023, by and between the Company and Marilee Moy Exhibit 10.1 Separation Agreement and Release THIS SEPARATION AGREEMENT AND RELEASE is entered into between Marilee Moy (the “Executive”) and Akoya Biosciences, Inc. (the “Company”). 1.Separation. The Executive’s employment with the Company and any of the Executive’s other roles with the Company shall end effective June 7, 2023 (the “Separation Date”). a. The Executive hereby waives all severance |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 3, 2023 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2023 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission F |
|
| June 28, 2023 |
Exhibit 10.1 Separation Agreement and Release THIS SEPARATION AGREEMENT AND RELEASE is entered into between Ehab El-Gabry (the “Executive”) and Akoya Biosciences, Inc. (the “Company”) as a condition to the Executive receiving the severance benefits (“Severance Benefits”) to be provided to the Executive by the Company pursuant to the Company’s Executive Severance Plan, dated March 23, 2022 (the “Se |
|
| June 13, 2023 |
AKYA / Akoya Biosciences Inc / Schindel Yair Chaim - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Akoya Biosciences, Inc. (Name of Issuer) Common Stock, Par Value $0.00001 per Share (Title of Class of Securities) 00974H104 (CUSIP Number) June 12, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| June 12, 2023 |
AKOYA BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK Exhibit 99.2 AKOYA BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK MARLBOROUGH, Mass., June 7, 2023 (GLOBE NEWSWIRE) - Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the pricing of its public offering of 8,700,000 shares of common stock (the “Offering”) at a public offering price of $5.00 per share for gross proceeds of approximatel |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 7, 2023 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 12, 2023 |
Exhibit 1.1 Execution Version Akoya Biosciences, Inc. 8,700,000 Shares of Common Stock Underwriting Agreement June 7, 2023 Morgan Stanley & Co. LLC Piper Sandler & Co. c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Piper Sandler & Co. U.S. Bancorp Center, 800 Nicollet Mall Minneapolis, Minnesota 55402 As Representatives of the several Underwriters listed in Schedule 1 here |
|
| June 12, 2023 |
AKOYA BIOSCIENCES ANNOUNCES PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 AKOYA BIOSCIENCES ANNOUNCES PUBLIC OFFERING OF COMMON STOCK MARLBOROUGH, Mass., June 7, 2023 (GLOBE NEWSWIRE) - Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has launched an underwritten public offering of shares of its common stock (the “Offering”). In addition, Akoya expects to grant the underwriters a 30-day option to purchase ad |
|
| June 9, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-268214 PROSPECTUS SUPPLEMENT (To Prospectus dated November 21, 2022) 8,700,000 Shares Common Stock We are offering 8,700,000 shares of our common stock. Our common stock trades on The Nasdaq Global Select Market under the symbol “AKYA.” On June 6, 2023, the last reported sale price of our common stock on The Nasdaq Global Se |
|
| June 7, 2023 |
Exhibit 99.1 Investor Presentation June 2023 2 Akoya Disclaimer Disclaimer Akoya Biosciences, Inc. (the "Company") has filed a registration statement (including a preliminary prospectus supplement and an accompanying prospectus) with the Securities Exchange Commission ("SEC") for the offering to which this communication relates. Before you invest, you should read the prospectus in that registratio |
|
| June 7, 2023 |
SUBJECT TO COMPLETION, DATED JUNE 7, 2023 TABLE OF CONTENTS The information contained in this preliminary prospectus supplement is not complete and may be changed. |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 7, 2023 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 1, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2023 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 9, 2023 |
Offer Letter, dated January 30, 2023, by and between the Registrant and Johnny Ek Exhibit 10.1 FRIDAY, JANUARY 27, 2023 Dear Johnny, We are very pleased to extend to you an offer of employment as Chief Financial Officer reporting to Brian McKelligon, Chief Executive Officer. This letter confirms the terms of your employment. Compensation Salary: Akoya Biosciences, Inc. will pay you a salary of $400,000.00 per year, as an exempt level employee, which is payable on a semi-monthly |
|
| May 9, 2023 |
Offer Letter, dated January 31, 2023, by and between the Registrant and Jennifer Kamocsay Exhibit 10.2 TUESDAY, JANUARY 31, 2023 Dear Jennifer, We are very pleased to extend to you an offer of employment as General Counsel reporting to Brian McKelligon, Chief Executive Officer. This letter confirms the terms of your employment. Compensation Salary: Akoya Biosciences, Inc. will pay you a salary of $380,000.00 per year, as an exempt level employee, which is payable on a semi-monthly pay |
|
| May 8, 2023 |
Exhibit 99.1 Akoya Reports Record Revenue in the First Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance May 8, 2023 Q1 2023 revenue $21.4 million, 27% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million MARLBOROUGH, Mass.— Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter end |
|
| May 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2023 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 20, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 20, 2023 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| March 20, 2023 |
Akoya Biosciences Announces Leadership Transition Exhibit 99.1 Akoya Biosciences Announces Leadership Transition Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer Johnny Ek Appointed as new Chief Financial Officer MARLBOROUGH, Mass., Mar. 20, 2023 (GLOBE NEWSWIRE) - Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Chief Financial Officer Joe Driscoll is reti |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2023 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| March 7, 2023 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock of Akoya Biosciences, Inc. (“we,” “us” and “our”) is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our Amended and Restated Certificate of Incorporation (“Certificate of Inco |
|
| March 7, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 Registration No. |
|
| March 7, 2023 |
Description of the Registrant’s capital stock Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock of Akoya Biosciences, Inc. (“we,” “us” and “our”) is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our Amended and Restated Certificate of Incorporation (“Certificate of Inco |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40 |
|
| March 7, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Akoya Biosciences, Inc. |
|
| March 7, 2023 |
Exhibit 10.22 Execution Version AMENDMENT NO. 3 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) This AMENDMENT NO. 3 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of the 7th day of November, 2022, by and among AKOYA BIOSCIENCES, INC., a Delaware corporation (“Borrower”), MIDCAP FINANCIAL TRUST, a Delaware statutory trust, as Agent (in such capacity, together with its succ |
|
| March 6, 2023 |
Exhibit 99.1 Akoya Reports Record Revenue in the Fourth Quarter of 2022 and Provides Full Year 2023 Revenue Guidance March 6, 2023 Q4 2022 revenue $21.2 million and FY 2022 revenue $74.9 million FY 2023 revenue guidance range $95-98 million MARLBOROUGH, Mass.— Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarte |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 6, 2023 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission F |
|
| February 15, 2023 |
AKYA / Akoya BioSciences, Inc. / PSC Capital Partners LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 (Amendment #1) Akoya Biosciences, Inc. |
|
| February 14, 2023 |
AKYA / Akoya BioSciences, Inc. / PSC Capital Partners LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 (Amendment #1) Akoya Biosciences, Inc. |
|
| February 7, 2023 |
AKYA / Akoya BioSciences, Inc. / Hudson Executive Capital LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Akoya Biosciences, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 00974H104 (CUSIP Number) Jeremy Nierman Hudson Executive Capital LP c/o Cadwalader, Wickersham & Taft LLP 200 Liberty Street New York, NY 10281 (212) |
|
| January 12, 2023 |
Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2022 Exhibit 99.1 Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2022 MARLBOROUGH, Mass. — January 8, 2023 — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022. Akoya reported the following preliminary financial results for the fourt |
|
| January 12, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2023 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| December 2, 2022 |
AKYA / Akoya BioSciences, Inc. / Hudson Executive Capital LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Akoya Biosciences, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 00974H104 (CUSIP Number) Michael D. Pinnisi Hudson Executive Capital LP c/o Cadwalader, Wickersham & Taft LLP 200 Liberty Street New York, NY 10281 (2 |
|
| November 17, 2022 |
As filed with the Securities and Exchange Commission on November 16, 2022 As filed with the Securities and Exchange Commission on November 16, 2022 Registration No. |
|
| November 17, 2022 |
CORRESP 1 filename1.htm VIA EDGAR November 17, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Ben Richie Re: Akoya Biosciences, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-268214 Dear Mr. Richie, Pursuant to Rule 461 under the Securities Act of 19 |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 7, 2022 |
Form of indenture for senior debt securities and the related form of senior debt security. Exhibit 4.1 AKOYA BIOSCIENCES, INC. ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF ? , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page Article One - DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 Section 101. Definitions 2 Section 102. Compliance Certificates and Opinions 11 Section 103. Form of Documents Delivered to Trustee 12 Section 104. Acts of Holders 12 Section 105. Notices |
|
| November 7, 2022 |
As filed with the Securities and Exchange Commission on November 7, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 7, 2022 Registration No. |
|
| November 7, 2022 |
Exhibit 1.2 AKOYA BIOSCIENCES, INC. EQUITY DISTRIBUTION AGREEMENT November 7, 2022 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this ?Agreement?), Akoya Biosciences, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell from time to time through Piper Sandler & Co. (the ?Agent |
|
| November 7, 2022 |
Exhibit 4.2 AKOYA BIOSCIENCES, INC. ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF ???????????? , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page??? Article One - DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 SECTION 101. Definitions 2 SECTION 102. Compliance Certificates and Opinions 12 SECTION 103. Form of Documents Delivered to Trustee 13 SECTION 104. Acts of Holders 13 |
|
| November 7, 2022 |
Exhibit 99.1 ? Akoya Reports Record Revenue with 40% YoY Growth in the Third Quarter and Raises Full Year 2022 Revenue Guidance ? November 7, 2022 ? Q3 2022 revenue $18.9 million, 40% y/y growth Raising FY 2022 revenue guidance range to $73-75 million ? MARLBOROUGH, Mass.? Akoya Biosciences, Inc. (Nasdaq: AKYA) (?Akoya?), The Spatial Biology Company?, today announced its financial results for the |
|
| November 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): November 7, 2022 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) ? ?? ? ? ? ? Delaware 001-40344 47-5586242 (State or other jurisdiction of incorp |
|
| November 7, 2022 |
EX-FILING FEES Calculation of Filing Fee Tables Form S-3 (Form Type) Akoya Biosciences, Inc. |
|
| September 13, 2022 |
EXHIBIT 3 Schedule of Transactions in Shares The following table sets forth all transactions with respect to Shares effected in the last sixty days by the Reporting Persons or on behalf of the Reporting Persons in respect of the Shares, inclusive of any transactions effected through 4:00 pm, New York City time, on September 13, 2022. |
|
| September 13, 2022 |
AKYA / Akoya BioSciences, Inc. / Hudson Executive Capital LP - SCHEDULE 13DA Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Akoya Biosciences, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 00974H104 (CUSIP Number) Michael D. Pinnisi Hudson Executive Capital LP c/o Cadwalader, Wickersham & Taft LLP 200 Liberty Street New York, NY 10281 (2 |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 9, 2022 |
Offer Letter, dated April 1, 2022, by and between Registrant and Ehab El-Gabry ? WEDNESDAY, MARCH 30, 2022 ? ? ? ? Dear Ehab,This letter supersedes our letter dated February 11, 2022 ? We are very pleased to confirm our offer of employment as Chief Medical Officer reporting to Brian Mckelligon, Chief Executive Officer. |
|
| August 9, 2022 |
Execution Version amendment no. 1 to CREDIT AND SECURITY AGREEMENT (TERM LOAN) This AMENDMENT NO. 1 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this ?Agreement?) is made as of the 21st day of March, 2022, by and among AKOYA BIOSCIENCES, INC., a Delaware corporation (?Borrower?), MidCap FINANCIAL Trust, a Delaware statutory trust, as Agent (in such capacity, together with its successors and assig |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): August 8, 2022 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) ? ?? ? ? ? ? Delaware 001-40344 47-5586242 (State or other jurisdiction of incorpor |
|
| August 8, 2022 |
Exhibit 99.1 ? Akoya Reports Second Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance ? August 8, 2022 ? Q2 2022 revenue $17.9 million, 37% y/y growth Raising FY 2022 revenue guidance range to $71-74 million ? MARLBOROUGH, Mass.? Akoya Biosciences, Inc. (Nasdaq: AKYA) (?Akoya?), The Spatial Biology Company?, today announced its financial results for the second quarter endin |
|
| June 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2022 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 2, 2022 |
Exhibit 10.1 Execution Version AMENDMENT NO. 2 to CREDIT AND SECURITY AGREEMENT (TERM LOAN) This AMENDMENT No. 2 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this ?Agreement?) is made as of the 1st day of June, 2022, by and among AKOYA BIOSCIENCES, INC., a Delaware corporation (?Borrower?), MidCap FINANCIAL Trust, a Delaware statutory trust, as Agent (in such capacity, together with its successor |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2022 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2022 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 5, 2022 |
Exhibit 99.1 Akoya Reports First Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance May 5, 2022 Q1 2022 revenue $16.9 million, 38% growth over prior year period Raising FY 2022 revenue guidance range to $70-73 million MARLBOROUGH, Mass.— Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 19, 2022 |
DEF 14A 1 tm2212803-1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the |
|
| March 29, 2022 |
Executive Severance Plan, effective March 23, 2022. Exhibit 10.1 AKOYA BIOSCIENCES, INC. Executive SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION (Effective March 23, 2022) This document sets forth all applicable terms of the Akoya Biosciences, Inc. Executive Severance Plan (this ?Plan?) of Akoya Biosciences, Inc., a Delaware corporation (the ?Company?), for its benefit and the benefit of its affiliates (including any direct or indirect subsidiary com |
|
| March 29, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 23, 2022 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| March 15, 2022 |
As filed with the Securities and Exchange Commission on March 14, 2022 As filed with the Securities and Exchange Commission on March 14, 2022 Registration No. |
|
| March 15, 2022 |
Offer Letter, dated December 2, 2021, by and between the Registrant and Marilee Moy Exhibit 10.17 December 2, 2021 Marilee Moy [***] [***] Issued via DocuSign: Email: [***] Dear Marilee, We are very excited about the prospects of your joining Akoya Biosciences, Inc. Should you accept this offer and upon successful completion of a pre-employment background check and drug screen we look forward to having you join the company In January 2022. This letter confirms the terms of your e |
|
| March 15, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Akoya Biosciences, Inc. |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 14, 2022 |
Exhibit 99.1 ? Akoya Reports Fourth Quarter and Full Year 2021 Operating Results and Provides 2022 Financial Outlook ? March 14, 2022 ? Q4 2021 revenue $16.2 million and FY 2021 revenue $54.9 million FY 2022 revenue guidance $69 - 71 million ? MARLBOROUGH, Mass.? Akoya Biosciences, Inc. (Nasdaq: AKYA) (?Akoya?), The Spatial Biology Company?, today announced its financial results for the fourth qua |
|
| March 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): March 14, 2022 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) ? ?? ? ? ? ? Delaware 001-40344 47-5586242 (State or other jurisdiction of incorpor |
|
| February 25, 2022 |
AKYA / Akoya BioSciences, Inc. / PSC Capital Partners LLC Passive Investment SC 13G 1 psccp13g02142022.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Akoya Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 00974H104 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the a |
|
| February 14, 2022 |
AKYA / Akoya BioSciences, Inc. / Telegraph Hill Partners III, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Akoya Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 00974H104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| January 10, 2022 |
Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021 Exhibit 99.1 Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021 MARLBOROUGH, Mass. ? January 10, 2022 ? Akoya Biosciences, Inc. (Nasdaq: AKYA) (?Akoya?), The Spatial Biology Company?, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2021. Akoya reported the following preliminary financial results for the four |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2022 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commissio |
|
| December 16, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2021 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commissi |
|
| December 16, 2021 |
Exhibit 99.1 Spatial Day 2021 December 15, 2021 2 Disclaimer Cautionary Note Regarding Forward-Looking Statements This presentation includes express and implied ?forward-looking statements.? In some cases, you can identify forward-looking statements by terms such as ? anticipate,? ?estimate,? ?expect,?? intend,?? may,?? might,?? plan,?? project,?? will,?? would,?? should,?? could,? ?can,?? predict |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 8, 2021 |
Exhibit 99.1 ? Akoya Reports Third Quarter 2021 Financial Results and Issues Full Year 2021 Guidance ? November 8, 2021 ? Q3 revenue $13.5 million, the highest in Akoya?s history and an increase of 35% over prior year ? MARLBOROUGH, Mass.? Akoya Biosciences, Inc. (Nasdaq: AKYA) (?Akoya?), The Spatial Biology Company?, today announced its financial results for the third quarter ending September 30, |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): November 8, 2021 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) ? ?? ? ? ? ? Delaware 001-40344 47-5586242 (State or other jurisdiction of incorp |
|
| October 18, 2021 |
EXHIBIT 1 Joint Filing Agreement The undersigned hereby agree to jointly prepare and file with regulatory authorities this Schedule 13D and any future amendments thereto reporting each of the undersigned?s ownership of securities of the Company named herein, and hereby affirm that such Schedule 13D is being filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934. |
|
| October 18, 2021 |
EXHIBIT 2 Schedule of Transactions in Shares The following table sets forth all transactions with respect to Shares effected in the last sixty days by the Reporting Persons or on behalf of the Reporting Persons in respect of the Shares, inclusive of any transactions effected through 4:00 pm, New York City time, on October 18, 2021. |
|
| October 18, 2021 |
AKYA / Akoya BioSciences, Inc. / Hudson Executive Capital LP - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Akoya Biosciences, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 00974H104 (CUSIP Number) Michael D. Pinnisi Hudson Executive Capital LP c/o Cadwalader, Wickersham & Taft LLP 200 Liberty Street New York, NY 10281 (212) 521-8495 Copie |
|
| September 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 16, 2021 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commiss |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2021 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| August 10, 2021 |
Exhibit 99.1 ? Akoya Reports 53% Revenue Growth in the Second Quarter of 2021 ? MARLBOROUGH, Mass. ? August 10, 2021 ? Akoya Biosciences, Inc. (Nasdaq: AKYA) (?Akoya?), The Spatial Biology Company?, today announced its financial results for the second quarter ending June 30, 2021. ? Second Quarter Financial Highlights ? ? Total revenue for the second quarter of 2021 was $13.1 million, as compared |
|
| June 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 11, 2021 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission F |
|
| May 28, 2021 |
AKYA / Akoya BioSciences, Inc. / Telegraph Hill Partners III, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.)* Akoya Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 00974H104 (CUSIP Number) April 20, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38873 Akoya Bio |
|
| May 18, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2021 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 18, 2021 |
Exhibit 99.1 Akoya Reports First Quarter 2021 Financial Results and Issues Full Year 2021 Guidance MARLBOROUGH, Mass. ? May 18, 2021 ? Akoya Biosciences, Inc. (Nasdaq: AKYA) (?Akoya?), The Spatial Biology Company?, today announced its financial results for the first quarter ending March 31, 2021. First Quarter Financial Highlights: ? Total revenue for the first quarter of 2021 was $12.2 million, a |
|
| April 23, 2021 |
As filed with the Securities and Exchange Commission on April 23, 2021 Registration No. |
|
| April 23, 2021 |
Form of Notice of Grant of Stock Option under the 2021 Equity Incentive Plan. Exhibit 99.4 Akoya Biosciences, Inc. NOTICE OF GRANT OF STOCK OPTION (For U.S. Participants) Akoya Biosciences, Inc. (the ?Company?) has granted to the Participant an option (the ?Option?) to purchase certain shares of Stock pursuant to the Akoya Biosciences, Inc. 2021 Equity Incentive Plan (the ?Plan?), as follows: Participant: Employee ID: Date of Grant: Number of Option Shares: , subject to adj |
|
| April 23, 2021 |
Form of Stock Option Agreement under 2021 Equity Incentive Plan. Exhibit 99.3 Akoya Biosciences, Inc. STOCK OPTION AGREEMENT (For U.S. Participants) Akoya Biosciences, Inc. (the ?Company?) has granted to the Participant named in the Notice of Grant of Stock Option (the ?Grant Notice?) to which this Stock Option Agreement (the ?Option Agreement?) is attached an option (the ?Option?) to purchase certain shares of Stock upon the terms and conditions set forth in t |
|
| April 20, 2021 |
Amended and Restated Bylaws of the Registrant Exhibit 3.2 AMENDED AND RESTATED Bylaws of AKOYA BIOSCIENCES, INC. Effective as of April 20, 2021 ARTICLE I CORPORATE OFFICES 1.1 Registered Office. The address of the registered office of Akoya BioSciences, Inc. (the ?Corporation?) in the State of Delaware, and the name of its registered agent at such address, shall be as set forth in the Corporation?s certificate of incorporation, as the same ma |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 20, 2021 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40344 47-5586242 (State or other jurisdiction of incorporation) (Commission |
|
| April 20, 2021 |
Amended and Restated Certificate of Incorporation of the Registrant Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AKOYA BIOSCIENCES, INC. a Delaware corporation (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Akoya BioSciences, Inc., (the ?Corporation?) a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?DGCL?), DOES HE |
|
| April 19, 2021 |
6,580,000 Shares Akoya Biosciences, Inc. Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(4)? ?Registration No. 333-254760? Prospectus 6,580,000 Shares Akoya Biosciences, Inc. Common Stock ? This is the initial public offering of shares of common stock of Akoya Biosciences, Inc. All of the 6,580,000 shares of common stock being sold in this offering are being sold by us. Prior to this offering, there has been no public market for our com |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 47-5586242 (State of incorporation or organization) (I.R.S. Employer Identification No.) 100 Campus Drive, 6t |
|
| April 13, 2021 |
April 13, 2021 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attn: Jeffrey Gabor Dillon Hagius Angela Connell Kristin Lochhead Re: Akoya Biosciences, Inc. |
|
| April 13, 2021 |
J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Piper Sandler & Co. U.S. Bancorp Center, 800 Nicollet Mall Minneapolis, Minnesota 55402 April 13, 2021 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attn: Jeffrey Gabor Dil |
|
| April 12, 2021 |
Akoya Biosciences, Inc. 2021 Employee Stock Purchase Plan Exhibit 10.3 AKOYA BIOSCIENCES, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN Table of Contents Page 1. Establishment, Purpose and Term of Plan 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction 1 2.1 Definitions 1 2.2 Construction 5 3. Administration 5 3.1 Administration by the Committee 5 3.2 Authority of Officers 6 3.3 Power to Adopt Sub-Plans or Varying Terms with |
|
| April 12, 2021 |
Offer Letter, dated March 2, 2021, by and between Registrant and Frederic Pla EX-10.16 7 tm212065d11ex10-16.htm EXHIBIT 10.16 Exhibit 10.16 March 2, 2021 Frederic Pla, Ph.D. [***] Dear Frederic, We are very excited about the prospects of your joining Akoya Biosciences, Inc. Should you accept this offer and upon successful completion of a pre-employment background check and drug screen we look forward to having you join the company on a date that is mutually convenient for b |
|
| April 12, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 12, 2021. |
|
| April 12, 2021 |
Akoya Biosciences, Inc. 2021 Equity Incentive Plan and form of stock option agreement thereunder Exhibit 10.2 AKOYA BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN Table of Contents Page 1. Establishment, Purpose and Term of Plan 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction 1 2.1 Definitions 1 2.2 Construction 8 3. Administration 8 3.1 Administration by the Committee 8 3.2 Authority of Officers 9 3.3 Administration with Respect to Insiders 9 3.4 Powers o |
|
| April 12, 2021 |
Form of Underwriting Agreement. EX-1.1 2 tm212065d11ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 Akoya Biosciences, Inc. [-] Shares of Common Stock Underwriting Agreement [-], 2021 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Piper Sandler & Co. c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Piper Sandler & Co. U.S. Bancorp Center, 80 |
|
| April 12, 2021 |
Amended and Restated Certificate of Incorporation, as currently in effect. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AKOYA BIOSCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Akoya Biosciences, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That th |
